Member Info for Aether

Green bin it.

Don't feed it.

Skippy - A TO is my preference as well. Synairgen have a fantastic product but it will come to market with a larger pharmaceutical company.

They will have the political clout as well as the financial clout. I suspect politics has played a significant role with Covid drugs.

Who wants to wait for more clinical trials?

What can it be?

Data from the deep dive?

If there is nothing new, why wait this long?

It may be information that doesn't require an RNS.

Would RM turn up to give bad news?

How could Science Bio and Synairgen benefit one another?

Something must be happening otherwise why do it after all the time that has elapsed?

Perhaps he's just finally showing his face and doing what Wigster said.

What's the link between SNG and Science Bio, M?

Polygon, hopefully, will keep them on point.

They are in deep and will want an exit with maximum value in a reasonable time.

Do you think there is a realistic prospect of recouping losses with good deep dive data and a TO?

Thank you, Tornadotony.

Does this have to be done by the end of this tax year?

How long does this last for?

Thank you.

"Most of us are just holding on. Hoping. Accepting it is years, not days or months until we recover a paper loss!"

Years is too long.

Time to wait for a big stock market crash and reinvest in the aftermath.

What influence do you think Polygon have on them?

Thank you, Manifesto.

The drug works.

I trust Polygon will keep Synairgen on point now.

Manifesto - The drug does work. The deep dive data needs to be good AND we need to be put on a suitable trial.
Then a TO to recoup some losses.

Is it a miracle to recoup some losses?

"... or even just the numbers achieved with the same results... happy days for us all."

How so?

Do you mean by having different end-points to determine success?

Do you think a big Pharma might make a TO on the basis of good deep dive, etc data?

Perhaps a more experienced company will be in a better position to bring it to market?